Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of ...
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
来自MSN2 个月
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
The treatment landscape for relapsed or refractory (R/R) mNPM1 AML remains challenging ... and mixed lineage leukaemia (MLL) fusion proteins, which are key drivers of leukaemia.